Literature DB >> 25858567

Signal identification in addictovigilance: the functioning of the French system.

Emilie Jouanjus1, Valérie Gibaja2, Jean-Pierre Kahn3, Françoise Haramburu4, Amélie Daveluy4.   

Abstract

The French addictovigilance network (addictovigilance: surveillance of addiction), composed of 13 Addictovigilance Centres, was set up in 1990 in order to achieve reliable surveillance and evaluation of abuse and dependence cases due to psychoactive substances (alcohol and tobacco excepted). The detection of safety signals is one of the roles of the addictovigilance centres. Signals from spontaneous reports need to be analyzed before further communication. In addictovigilance, signals may be linked to adverse effects (deaths, pathological signs), to products (new psychoactive substances with potentially dangerous effects) or to practices (new administration routes, new contexts of use). These signals are provided by numerous partners among whom the addictovigilance network has to raise awareness about information that may possibly be an alert signal. The watchful attitude of all partners will make it possible that signals will be, after analyze, considered as true alerts. The addictovigilance network collects data, assess the potential for addiction of psychoactive drugs to provide information on the risk of addiction and give opinions for public health decisions (harm reduction or prevention programs, psychoactive substances control, health alerts).
© 2015 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25858567     DOI: 10.2515/therapie/2015011

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  16 in total

1.  Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction.

Authors:  Caroline Diot; Céline Eiden; Anne Roussin; Anne Batisse; Alexandra Boucher; François Chavant; Amélie Daveluy; Hélène Donadieu-Rigole; Hélène Peyrière
Journal:  Eur J Clin Pharmacol       Date:  2015-09-02       Impact factor: 2.953

2.  Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital.

Authors:  Margaux Lafaurie; Liselotte Pochard; Clémence Lotiron; Laurent Molinier; Maryse Lapeyre-Mestre; Emilie Jouanjus
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 2.859

3.  High opioids tolerance due to transmucosal fentanyl abuse.

Authors:  Celine Eiden; Olivier Mathieu; Hélène Donnadieu-Rigole; Cécile Marrot; Hélène Peyrière
Journal:  Eur J Clin Pharmacol       Date:  2017-06-03       Impact factor: 2.953

4.  Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter".

Authors:  Emilie Jouanjus; Michel Mallaret; Joëlle Micallef; Camille Ponté; Anne Roussin; Maryse Lapeyre-Mestre
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

5.  Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.

Authors:  Jean-Baptiste Bossard; Camille Ponté; Julie Dupouy; Maryse Lapeyre-Mestre; Emilie Jouanjus
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

6.  Early signal of diverted use of tropicamide eye drops in France.

Authors:  Camille Ponté; Christian Pi; Aurore Palmaro; Emilie Jouanjus; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2017-03-27       Impact factor: 4.335

7.  Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior.

Authors:  Edouard-Jules Laforgue; Marion Istvan; Benoit Schreck; Marie Mainguy; Pascale Jolliet; Marie Grall-Bronnec; Caroline Victorri-Vigneau
Journal:  J Clin Med       Date:  2022-04-13       Impact factor: 4.964

8.  Identifying Life-Threatening Admissions for Drug Dependence or Abuse (ILIADDA): Derivation and Validation of a Model.

Authors:  Tri-Long Nguyen; Thierry Boudemaghe; Géraldine Leguelinel-Blache; Céline Eiden; Jean-Marie Kinowski; Yannick Le Manach; Hélène Peyrière; Paul Landais
Journal:  Sci Rep       Date:  2017-03-14       Impact factor: 4.379

Review 9.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

10.  Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.

Authors: 
Journal:  BMC Fam Pract       Date:  2016-03-01       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.